Jubilant Life Sciences provides update on subsidiary

Jubilant Pharma, Singapore issues Unsecured High Yield Bonds

Jubilant Life Sciences announced that its wholly owned subsidiary, Jubilant Pharma, Singapore has successfully completed on 06 October 2016, a debt issue of its rates unsecured high yield bonds (Notes) bearing interest of 4.875% per annum. The Notes were issued at par in a principal amount of USD 300 million and will mature in October 2021. The Notes will be listed on Singapore Exchange Securities Trading.

Powered by Capital Market - Live News